Format

Send to

Choose Destination
Cancer Cell. 2003 Apr;3(4):305-7.

Cdk2 dethroned as master of S phase entry.

Author information

1
Department of Pathology, Harvard Medical School, Boston, MA 02115, USA. phil_hinds@hms.harvard.edu

Abstract

The prevailing view of cdk2 as a critical regulator of cell cycle progression and optimal therapeutic target in cancer cells is now challenged by the observation that tumor cells deficient in cdk2 protein and kinase activity are not impaired in proliferation.

PMID:
12726855
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center